This review examines recent advancements in nanoparticle( s) (NPs) delivery systems, with a focus on ... lipid nanoparticles (LNPs)... We discussed various NP platforms and their applications, such as ... dry powder formulations of mRNA-loaded LNPs for pulmonary delivery, and LNP-mediated siRNA delivery for respiratory infections.
The gap explicitly calls for novel vaccine technologies and improved therapeutic delivery, and this item is a concrete non-viral platform for mRNA, siRNA, and CRISPR cargo. The summary also mentions respiratory infection use cases and dry-powder pulmonary formulations, which plausibly align with scalable interventions for infectious disease.
Assumptions: Assumes nucleic-acid-based vaccines or therapeutics are in scope for the intervention need.
Missing evidence: No direct evidence here on low-resource deployment, cold-chain independence, cost of goods, or success for the specific diseases named in the gap.
This review explores virus biomimetic delivery systems, focusing on virus-like particles (VLPs) and virosomes as promising platforms for vaccine and therapeutic development. Virosomes are reconstituted viral envelopes that retain functional glycoproteins but lack a nucleocapsid.
The summary directly frames virosomes as platforms for vaccine and therapeutic development, which matches the gap's need for better vaccines and interventions. As a reconstituted viral-envelope platform, it is at least mechanistically relevant to antigen delivery and immunization strategies.
Assumptions: Assumes the platform can be adapted beyond the review context to pathogens relevant to global health.
Missing evidence: No pathogen-specific efficacy, manufacturability, stability, low-resource suitability, or replication data are provided.
Species D adenoviruses, such as human adenovirus type 10 (HAdV-D10), are promising candidates due to low seroprevalence in humans... support the advancement of HAdV-D10 as a next-generation platform for gene delivery and vaccine development.
This item is explicitly described as a platform for gene delivery and vaccine development, which is directly relevant to the vaccine under-provisioning part of the gap. The noted low human seroprevalence could be advantageous for vector-based vaccination strategies.
Assumptions: Assumes adenoviral vaccine platforms are acceptable for the target use cases.
Missing evidence: No direct evidence on clinical performance, manufacturability, thermostability, low-resource deployment, or applicability to the named diseases.
A multitude of substances are currently under investigation for the preparation of nanoparticles for drug delivery, varying from biological substances like albumin, gelatine and phospholipids for liposomes
Liposomes are a concrete drug-delivery platform and could plausibly support formulation work for therapeutics or vaccine cargo. That makes them relevant to the gap's call for low-cost, effective interventions, but the supplied evidence is generic.
Assumptions: Assumes general nanocarrier formulation platforms are useful for early intervention development.
Missing evidence: The summary does not provide infectious-disease, vaccine, malnutrition, low-resource, or clinical translation evidence.
Exosomes possess antigens and immunostimulatory molecules and can serve as cell-free vaccines to induce antitumor immunity. In addition, given their stability, low immunogenicity, and targeting ability, exosomes represent ideal drug delivery systems in tumor immunotherapy.
The summary states that exosomes can function as cell-free vaccines and as drug delivery systems, so they are at least directionally relevant to vaccine and therapeutic development. Their stated stability and low immunogenicity could matter for intervention design.
Assumptions: Assumes the vaccine and delivery properties described in tumor immunotherapy may generalize to infectious-disease applications.
Missing evidence: Evidence is centered on tumor immunotherapy, with no direct support here for global infectious diseases, low-resource deployment, manufacturing feasibility, or cost.
The review integrates data from in vitro, in silico, and clinical studies, including both classical detection strategies and emerging technologies such as clustered regularly interspaced short palindromic repeats (CRISPR)-based modulation, biosensors, and microfluidics.
Microfluidics is a plausible enabling assay/platform technology for faster screening or detection workflows, which could modestly support intervention development pipelines. However, the supplied summary does not directly connect it to vaccines, therapeutics, or malnutrition interventions.
Assumptions: Assumes platform integration and detection methods are relevant to accelerating R&D workflows.
Missing evidence: No direct evidence on use for vaccine development, therapeutic formulation, malnutrition research, or low-resource deployment is provided.